Korea Research Institute of Bioscience and Biotechnology

Korea Atomic Energy Research Institute

Proteometech Inc.

Chang Kyu Heo

Hai Min Hwang

Eun Wie Cho

Hye Jung Lee

Byung Chul Shin

Jeong Heon Ko

Kook Jin Lim

In Gyu Kim

Hyang Sook Yoo

Mi Kyung Woo

Jeong Heun Ko

Rae Kwon Kim

Jai Ha Lee

Chun Jeih Ryu

Mun Ju Choi

Yeon Jee Kahm

The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies or antigen-binding fragments thereof exhibit proliferation inhibitory activity of cancer cells so as to effectively prevent or treat cancer, and reduce the self-renewal ability of cancer stem cells to be usefully used even in the treatments of cancer with a poor prognosis in conventional anticancer treatments.

Anti-TM4SF4 antibody and uses thereof

Provided are an autoantibody specifically binding to an exosomal protein EIF3A (Eukaryotic translation initiation factor 3 subunit A) or a fragment including an antigen-binding site (paratope) thereof, a hybridoma cell line producing the autoantibody, a polypeptide having an amino acid sequence of an antigenic determinant (epitope) specifically binding to the autoantibody, a composition for diagnosing liver cancer including an agent measuring an expression level of the autoantibody or the fragment including the antigen-binding site thereof, a kit for diagnosing liver cancer including the composition, and a method of providing information for diagnosis of liver cancer by using the composition. Further, provided is a method of screening for a therapeutic agent for liver cancer by using an expression level of the autoantibody. When anti-EIF3A autoantibody of the present invention is used as a diagnostic marker for liver cancer, the incidence of liver cancer may be diagnosed at a high level only by using non-invasive biological samples. Furthermore, liver cancer may be easily diagnosed by using only the amino acid sequence identified in the present invention, leading to the effective development of diagnostic products such as a diagnostic kit for liver cancer.

Antigenic composition for detecting auto-antibody with specific response to exosomal protein EIF3A, and method for diagnosing liver cancer using antigenic composition

The present invention relates to an autoantibody specifically recognizing the epitope sequence of FASN (fatty acid synthase), more particularly, to the autoantibody or a fragment comprising an antigen-binding site thereof, a diagnostic composition for hepatocellular carcinoma comprising an agent capable of assessing the expression level of the autoantibody, a hybridoma cell line producing the autoantibody, a diagnostic kit for hepatocellular carcinoma comprising the composition, a method for detecting the autoantibody of hepatocellular carcinoma patient using the composition, and a method for screening a therapeutic agent for hepatocellular carcinoma by administering candidate materials for hepatocellular carcinoma treatment to confirm a reduction in the expression level of autoantibody.

Diagnostic marker for hepatocellular carcinoma comprising anti-FASN autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof

Growing community of inventors

Daejeon, South Korea

Chang Kyu Heo